Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis

Br J Dermatol. 2008 Sep;159(3):760-1. doi: 10.1111/j.1365-2133.2008.08729.x. Epub 2008 Jul 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal, Humanized
  • Drug Costs
  • Female
  • Humans
  • Immunosuppressive Agents / economics*
  • Male
  • Middle Aged
  • Netherlands
  • Psoriasis / drug therapy*
  • Psoriasis / economics*
  • Reimbursement Mechanisms / statistics & numerical data*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • efalizumab